Related Experiment Videos
Leukocyte-reduced transfusions in cardiac surgery results of an implementation trial
Neil Blumberg1, Joanna M Heal, Judith W Cowles
1Department of Pathology & Laboratory Medicine, University of Rochester Medical Center, NY 14642, USA.
Insights
Implementing leukocyte-reduced transfusions in cardiac surgery significantly reduced patient complications and hospitalization costs. This blood conservation strategy offers potential cost savings in healthcare settings.
Area of Science:
- Cardiovascular Surgery
- Transfusion Medicine
- Health Economics
Background:
- Leukocyte-reduced blood transfusions are utilized in various medical settings.
- The impact of leukocyte reduction on patient outcomes and costs in cardiac surgery requires further investigation.
Purpose of the Study:
- To evaluate the effectiveness and economic impact of implementing leukocyte-reduced transfusions in cardiac surgery patients.
- To compare complication rates and healthcare costs between patients receiving leukocyte-reduced and non-leukocyte-reduced blood transfusions.
Main Methods:
- An implementation trial comparing leukocyte-reduced transfusions (July-December 1998) with historical data (July-December 1997) in cardiac surgery patients.
- Analysis of preoperative and intraoperative variables, complication rates, and total costs of care per patient.
- Statistical comparison of outcomes between the two transfusion groups.
Main Results:
- A statistically significant decrease in mean complications per patient from 0.26 to 0.19 was observed with leukocyte-reduced transfusions.
- Overall mean costs of care per patient decreased from $27,615 in 1997 to $27,038 in 1998.
- Hospitalization costs decreased for patients undergoing cardiac surgery with leukocyte-reduced transfusions.
Conclusions:
- Implementation of leukocyte-reduced transfusions in cardiac surgery led to a reduction in patient complications.
- Leukocyte reduction in transfusions may be cost-neutral or cost-saving in specific healthcare scenarios.
- This strategy shows promise for improving patient outcomes and managing healthcare expenditures in cardiac surgery.
Abstract:
An implementation trial of leukocyte-reduced transfusions in cardiac surgery (primary coronary artery bypass graft and valve replacement) was performed from July to December 1998; comparisons were made with data from the same period in 1997. Patients from both periods were similar in important preoperative and intraoperative variables (age, sex, weight, number of units of RBCs transfused, ejection fraction). The mean total number of complications was statistically significantly decreasedfrom 0.26 complications per patient in the non-leukocyte-reduced to 0.19 in the leukocyte-reduced recipients. Overall, the mean +/- ISD costs of care per patient decreasedfrom 1997 ($27,615 +/- $33,973) to 1998 ($27,038 +/- $24,107). Mean costs decreased $1,700 per patient for recipients of leukocyte-reduced blood in 1998 compared with recipients of non-leukocyte-reduced blood in 1997 Mean costs increased $4,000 per patient in patients who did not receive transfusions in 1998 compared with 1997. Hospitalization costs decreased when leukocyte-reduced transfusions were implemented for patients undergoing cardiac surgery in our institution. Implementation of leukocyte reduction may be cost neutral or cost saving in at least some settings.